Posts Tagged ‘angiotensis receptor neprilysin inhibitor’

September 5th, 2014

Perspectives on PARADIGM-HF

The Editors present a distillation of reader comments on a popular post.

September 1st, 2014

Let’s Take a Close Look at PARADIGM-HF

Vinay Prasad explores three reasons why clinicians should have reservations about the findings from PARADIGM-HF.

August 30th, 2014

Will There Be a PARADIGM Shift in Treatment of Heart Failure?


John J.V. McMurray and Milton Packer, the two lead authors of the PARADIGM-HF trial, discuss the randomized comparison of angiotensin–neprilysin inhibition with the ACE inhibitor enalapril.

October 22nd, 2012

Selections from Richard Lehman’s Literature Review: October 22nd

This week’s topics include favorable lipid-level trends in U.S. adults, an angiotensin receptor neprilysin inhibitor for patients with HF and preserved systolic ejection fraction, and a long-term safety comparison of the Zotarolimus-eluting and Sirolimus-eluting coronary stents.